Finerenone has been studied in 135 papers since 2022: 28 trials and 23 observational studies in people, 1 in animals, 80 reviews; 120 in the past year. It is an approved medicine. The newest story, Nov 12, 2026: “Lower quality of life linked to worse heart outcomes”.
Finerenone reduces cardiorenal events in human trials involving people with type 2 diabetes and chronic kidney disease; independent labs report fewer heart failure hospitalizations. Cohort mortality associations differ; trials report increased hyperkalemia. Bayer funds papers, employs authors and sponsors trials; aging-focused trials are registered, while some trials across uses ended over a year ago without posted results.
126 findings in 58 papers from 2023 to 2026, 31 of them since April 2026
Independent labs found the same change in people. 26 independent labs in 17 countries; 74 trials, 6 about aging, 13 with no results posted.
Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
26 independent labs in 17 countries
6 findings against
74 trials, 6 about aging, 13 with no results posted
Studies of finerenone measured 62 outcomes, among them mortality, urine albumin-to-creatinine ratio and cardiorenal outcomes.
Mortality
↓downin humans2↔no changein humans1HR 0.55–0.91
3 studies
Finerenone is linked with lower mortality in humans (HFpEF receiving SGLT2 inhibitors vs spironolactone) (5.2% vs 10.6%; HR 0.55, 95% CI 0.42-0.72; p<0.001).
“finerenone was associated with lower hospitalization rates (29.4% vs 40.8%; HR 0.73, 95% CI 0.65-0.82; p<0.001), acute heart failure events (17.2% vs 26.4%; HR 0.67, 95% CI 0.58-0.79; p<0.001), acute kidney injury (23.0% vs 29.7%; HR 0.83, 95% CI 0.72-0.96; p=0.010), myocardial infarction (6.9% vs 10.8%; HR 0.70, 95% CI 0.55-0.90; p=0.004), emergency department visits (23.2% vs 30.7%; HR 0.83, 95% CI 0.72-0.95; p=0.007), all-cause mortality (5.2% vs 10.6%; HR 0.55, 95% CI 0.42-0.72; p<0.001)”
HumansHFpEF receiving SGLT2 inhibitors vs spironolactone1 year
Finerenone decreases urine albumin-to-creatinine ratio in humans (CKD and T2D; simultaneous initiation of finerenone and empagliflozin) (37% reduction; ratio of geometric mean change 0.63 (95% CI 0.58–0.69)).
“Between baseline and 14 days, the simultaneous initiation strategy was associated with a 37% reduction in UACR”
Human trialCKD and T2D; simultaneous initiation of finerenone and empagliflozin14 daysn = 526
Finerenone decreases urine albumin-to-creatinine ratio in humans (~40% lower).
“Baseline UACR was higher with greater frailty, but at month 4, finerenone was associated with an approximate 40% lower in albuminuria across all subgroups, which was significant compared with placebo (P < 0.001 for all subgroups).”
Finerenone decreases systolic blood pressure in humans (CKD and T2D; sequential or simultaneous initiation with SGLT2 inhibitors) (Sequential: −3.5 mm Hg (95% CI −5.1 to −2.0); simultaneous: −3.7 mmHg).
“Reductions in systolic blood pressure by day 30 were comparable between the sequential”
Human trialCKD and T2D; sequential or simultaneous initiation with SGLT2 inhibitors30 days
Finerenone increases serum potassium in humans (CKD and T2D; sequential or simultaneous initiation with SGLT2 inhibitors) (Sequential: +0.16 mmol/L (95% CI +0.12 to +0.21); simultaneous: +0.22 mmol/L).
“Finerenone resulted in a similar increase in serum potassium levels by day 30”
Human trialCKD and T2D; sequential or simultaneous initiation with SGLT2 inhibitors30 days
Finerenone increases serum potassium in humans (primary aldosteronism) (+0.39±0.05 mmol/L; normal concentration in 94.5% versus 61.8% at baseline).
“The mean increase in serum potassium concentration was 0.39±0.05 mmol/L, and 94.5% of patients exhibited a normal concentration after 12 weeks of treatment”
Human trialprimary aldosteronism20-40 mg/d12 weeks
Finerenone decreases urinary albumin-to-creatinine ratio in humans after empagliflozin monotherapy in type 2 diabetes and chronic kidney disease (-34.0%).
“and by 34.0% after finerenone substitution, relative to the end of empagliflozin monotherapy.”
Human trialafter empagliflozin monotherapy in type 2 diabetes and chronic kidney diseaseurine4 weeksn = 2
Finerenone is linked with lower urinary albumin-to-creatinine ratio in humans (dual and triple therapy, within-group change) (50.6% (dual-therapy); 46.9% (triple-therapy)).
“Within-group ln(UACR) decreased in both regimens [dual-therapy (50.6%, 28.3-65.9; P < 0.001)”
Humansdual and triple therapy, within-group changekidney6 monthsn = 83
“Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has also been shown to reduce kidney disease progression and cardiovascular events in patients with established diabetic CKD”
Finerenone decreases AHA PREVENT risk score progression in humans (Base-model least squares mean difference −0.018 at Month 48; p<0.01; full-model reduction from Month 4, p<0.0001).
“Finerenone significantly reduced the progression of PREVENTTM score relative to placebo at Month 48 using the base model”
Human trialType 2 diabetes and chronic kidney disease without prior cardiovascular disease; base model versus placebo48 monthsn = 7,050
Finerenone decreases non-fatal cardiovascular events in humans (Base-model HRs: low tertile 0.89 (95% CI 0.60–1.32), intermediate 1.11 (0.79–1.56), high 0.85 (0.65–1.11); interaction p=0.57).
“Finerenone demonstrated consistent CV benefit across AHA PREVENTTM-estimated risk levels.”
Human trialType 2 diabetes and chronic kidney disease without prior cardiovascular disease; comparison with placebo across baseline PREVENT risk tertilesn = 7,050
Finerenone increases potassium time-in-target range in humans (Compared with placebo; potassium target range 4.5-5.0 mmol/L) (8% (95% CI 7-9); median 38% vs. 23%).
“Randomization to finerenone increased TIR by 8% (95% CI 7-9) compared with placebo”
Human trialCompared with placebo; potassium target range 4.5-5.0 mmol/Lfirst year35% womensn = 18,991
Finerenone increases time in target systolic blood pressure range in humans (Heart failure with LVEF ≥40%; target systolic blood pressure 110–<130 mmHg) (4% (95% CI 2 to 5%)).
“4% (2 to 5%) with finerenone.”
Human trialHeart failure with LVEF ≥40%; target systolic blood pressure 110–<130 mmHgfirst year
Finerenone is associated with mortality in humans (2.1 vs 4.5 events/100 person-years; incidence rate difference -2.41 (95% CI -4.38 to -0.44)).
“finerenone initiation was associated with lower incidence rates of all-cause death (2.1 vs 4.5 events/100 person-years; incidence rate difference, -2.41; 95% CI, -4.38 to -0.44)”
HumansType 2 diabetes and chronic kidney disease without prior heart failure or ischemic heart disease; prior first-line SGLT2 inhibitor therapy; compared with steroidal MRAs18 months
Finerenone is linked with a lower risk of mortality in humans (HR 0.41; 95% CI 0.21-0.80).
“Finerenone users were associated with a lower risk of heart failure exacerbation (HR 0.51; 95% CI 0.35-0.76), all-cause mortality (HR 0.41; 95% CI 0.21-0.80)”
Finerenone is associated with hyperkalemia in humans (Patients with chronic kidney disease and type 2 diabetes; compared with nonusers) (HR 1.47, 95% CI 1.31–1.65).
“Finerenone initiators were more likely to experience hyperkalemia (HR, 1.47; 95% CI, 1.31-1.65).”
HumansPatients with chronic kidney disease and type 2 diabetes; compared with nonusersmale, 53%s
Finerenone is associated with hyperkalemia in humans (HR 1.35; 95% CI 1.11–1.69; risk-based analyses were not statistically significant).
“Hyperkalemia occurred more often with finerenone (HR 1.35; 95% CI: 1.11 to 1.69) although risk-based analyses did not reach statistical significance.”
HumansChronic kidney disease and type 2 diabetes; finerenone added to SGLT2 inhibitor therapy versus SGLT2 inhibitor monotherapy1 year
Finerenone is linked with a lower risk of acute kidney injury in humans (HFpEF receiving SGLT2 inhibitors vs spironolactone) (23.0% vs 29.7%; HR 0.83, 95% CI 0.72-0.96; p=0.010).
“acute kidney injury (23.0% vs 29.7%; HR 0.83, 95% CI 0.72-0.96; p=0.010)”
HumansHFpEF receiving SGLT2 inhibitors vs spironolactone1 year
Finerenone is linked with a lower risk of acute kidney injury in humans (chronic kidney disease, diabetes mellitus, and non-DM) (HR=0.59 to 0.72, p<0.001).
“finerenone was associated with a lower risk of acute kidney injury across CKD (HR=0.59) , DM (HR=0.72) , and non-DM (HR=0.41) phenotypes (p<0.001 for all)”
Humanschronic kidney disease, diabetes mellitus, and non-DM
Finerenone lowers the risk of composite cardiovascular outcome in humans (HR = 0.86; 95% CI: 0.78–0.95).
“The relative hazard reduction for the composite CV outcome was slightly lower within the primary data scope (HR = 0.86; 95% CI: 0.78–0.95; p = 0.0018) compared with the on-treatment data scope (HR = 0.81; 95% CI: 0.73–0.90; p = 0.0001) (shown in online suppl. Fig. S2).”
Finerenone is associated with composite cardiovascular outcome in humans (Patients with chronic kidney disease and type 2 diabetes; compared with nonusers) (HR 0.89, 95% CI 0.79–1.00).
“Finerenone initiators had lower risk of the composite CV outcome (HR, 0.89; 95% CI, 0.79-1.00)”
HumansPatients with chronic kidney disease and type 2 diabetes; compared with nonusersmale, 53%s
Finerenone is linked with a lower risk of heart failure in humans (HFpEF receiving SGLT2 inhibitors vs spironolactone) (17.2% vs 26.4%; HR 0.67, 95% CI 0.58-0.79; p<0.001).
“acute heart failure events (17.2% vs 26.4%; HR 0.67, 95% CI 0.58-0.79; p<0.001)”
HumansHFpEF receiving SGLT2 inhibitors vs spironolactone1 year
Finerenone is linked with a lower risk of major adverse cardiovascular events in humans (chronic kidney disease) (HR=0.45, 95% CI: 0.39-0.52, p<0.001).
Finerenone lowers the risk of kidney failure in humans.
“Finerenone demonstrated consistent reductions in the ≥57% and ≥40% kidney composite outcomes compared with placebo, with no heterogeneity between the frailty subgroups (P values for interaction = 0.93 and 0.76, respectively; Figure ).”
Finerenone lowers the risk of cardiovascular disease in humans.
“Across the three most frail quartiles, >Q1 to ≤Q2, >Q2 to ≤Q3, and >Q3, there was a consistent lower relative risk of the CV composite outcome in people treated with finerenone versus placebo”
Finerenone lowers the risk of composite kidney outcome in humans (HR = 0.76; 95% CI: 0.66–0.88).
“The effect of finerenone versus placebo on the composite kidney outcome appeared to be greater within the on-treatment data scope, which only included events observed up to 30 days after discontinuation of study of the drug (HR = 0.68; 95% CI: 0.57–0.81; p < 0.0001), than with the primary data scope (HR = 0.76; 95% CI: 0.66–0.88; p = 0.0001”
Finerenone lowers the risk of composite kidney outcome in humans (on-treatment) (HR 0.65, 95% CI 0.54-0.78).
“kidney: 1.09 vs. 1.71; CV: 2.98 vs. 3.78) as well as after discontinuation (kidney: 11.95 vs. 13.67; CV: 14.07 vs. 14.73). The effect of finerenone on composite kidney and CV outcomes appeared to be reduced after discontinuation (hazard ratio [HR] = 0.82; 95% confidence interval [CI] 0.66-1.02; HR = 0.93; 95% CI: 0.79-1.09, respectively) versus the time on-treatment (HR = 0.65; 95% CI: 0.54-0.78;”
Cardiovascular death and worsening heart failure events
↓downin humans1RR 0.66–1.07
1 study
Finerenone lowers the risk of cardiovascular death and worsening heart failure events in humans (RR 0.66 [95% CI, 0.52-0.83] in class II, RR 0.91 [95% CI, 0.76-1.07] in class III, RR 1.07 [95% CI, 0.77-1.49] in class I).
“Compared with placebo, finerenone reduced the risk of total worsening HF events and cardiovascular death, with no interaction between FI class and the effect of finerenone (class I: RR, 1.07 [95% CI, 0.77-1.49]; class II: RR, 0.66 [95% CI, 0.52-0.83]; class III: RR, 0.91 [95% CI, 0.76-1.07]; P for interaction =.77”
Finerenone lowers the risk of cardiovascular death and worsening heart failure events in humans (heart failure with LVEF >= 40%) (class I: RR 1.07; class II: RR 0.66; class III: RR 0.91; P for interaction = .77).
“In FINEARTS-HF, finerenone reduced the risk of total worsening HF events and cardiovascular death, and it improved symptoms; these effects were not modified by frailty status.”
Human trialheart failure with LVEF >= 40%once-dailyn = 5,952
Finerenone lowers the risk of composite kidney events in humans (HR 0.76; 95% CI 0.66–0.88).
“finerenone reduced composite CV (hazard ratio [HR] 0.86; 95% confidence interval [CI] 0.78–0.95) and kidney outcomes (HR 0.76; 95% CI 0.66–0.88)”
Human trialChronic kidney disease and type 2 diabetes; compared with placebo across systolic blood pressure variability quartilesMedian follow-up 3 years
Finerenone lowers the risk of composite cardiovascular events in humans (HR 0.86; 95% CI 0.78–0.95).
“finerenone reduced composite CV (hazard ratio [HR] 0.86; 95% confidence interval [CI] 0.78–0.95) and kidney outcomes (HR 0.76; 95% CI 0.66–0.88)”
Human trialChronic kidney disease and type 2 diabetes; compared with placebo across systolic blood pressure variability quartilesMedian follow-up 3 years
Finerenone lowers the risk of cardiovascular, kidney and mortality outcomes in women and men; no treatment heterogeneity by sex (all Pinteraction >.05).
“Finerenone conferred consistent benefits in women and men”
Human trialin women and men; no treatment heterogeneity by sex (all Pinteraction >.05)
Reviews of human studies describe improved kidney and cardiovascular outcomes with finerenone, alongside increased hyperkalemia and adverse-event discontinuation. A human preprint in heart failure with preserved ejection fraction reports fewer adverse renal outcomes but unchanged dementia or cognitive decline incidence over six months.
Across three trials, each 0.1-point lower quality-of-life score was linked to greater relative risk of cardiovascular death or heart failure hospitalization (hazard ratio…Across three trials, each 0.1-point lower quality-of-life score was linked to greater relative risk of cardiovascular death or heart failure hospitalization (hazard ratio 1.10).
Who was studied18,694 adults with cardiovascular-kidney-metabolic syndrome
What changedCardiovascular death or heart failure hospitalization risk was higher with poorer quality-of-life scores (hazard ratio 1.10 per 0.1-point decrease)
The catchWorse kidney function and more comorbidities could partly explain the link with poorer quality-of-life scores